Bank of New York Mellon Corp Sells 123,265 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Bank of New York Mellon Corp lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 26.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 345,329 shares of the medical research company's stock after selling 123,265 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.70% of Charles River Laboratories International worth $51,979,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CRL. Rothschild Investment LLC increased its position in Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after buying an additional 144 shares during the period. Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $37,000. GeoWealth Management LLC increased its holdings in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $48,000. Finally, Huntington National Bank grew its position in Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after buying an additional 164 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Robert W. Baird lifted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price target for the company from $188.00 to $182.00 in a report on Friday, May 23rd. Evercore ISI raised their target price on shares of Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and increased their price target for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Stock Up 0.4%

Shares of NYSE CRL traded up $0.55 during trading on Wednesday, hitting $154.97. The stock had a trading volume of 526,556 shares, compared to its average volume of 1,030,790. The firm has a fifty day moving average of $146.43 and a two-hundred day moving average of $151.17. The company has a market capitalization of $7.61 billion, a PE ratio of -238.42, a PEG ratio of 5.35 and a beta of 1.49. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business's revenue was down 2.7% compared to the same quarter last year. During the same period last year, the firm posted $2.27 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president owned 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).